Mar 11, 2017 | Compliance, Legal, and Malpractice, Instruments & Equipment, Laboratory Instruments & Laboratory Equipment, Laboratory Management and Operations, Laboratory News, Laboratory Operations, Laboratory Pathology
With less revenue flowing from reimbursements and more consumers footing the bill for diagnostic testing, counterbalancing lost revenue while better serving providers and patients is not an option for clinical labs and pathology groups—it is a must.
The year 2016 was one of continuing change for the healthcare industry. The result has been more pressure than ever in 2017 to meet the demands of informed consumers, while balancing new regulations. For clinical laboratories and anatomic pathology groups, these myriad changes have also resulted in a pressing need to achieve more with fewer resources, and at the same time finding ways to grow.
The good news is that because the typical medical laboratory houses an abundance of clinical and business data, and due to a renewed dependence on technology and informatics—it is now easier than ever for clinical labs to unlock the power of this data and embrace a set of “new rules” for survival.
DarkDaily.com is pleased to offer a recently published free White Paper exploring three of the critical rules innovative medical laboratories must take into account to combat the drastic changes occurring, and outlining a set of proactive steps that, when taken, will serve as a foundation for clinical success in 2017 and beyond. (more…)
Sep 17, 2016 | Digital Pathology, Laboratory Instruments & Laboratory Equipment, Laboratory Management and Operations, Laboratory Pathology, Laboratory Testing
Increased understanding of the genetic basis of an individual’s response to drugs, including how and how quickly a drug is metabolized (pharmacodynamics and pharmacokinetics), has created rich opportunities for the establishment and expansion of PgX services.
Expertise such as this that is beyond traditional lab medicine is crucial to the future success
of your laboratory.
Pharmacodynamics and pharmacokinetics have opened the door to a progressively personalized approach to drug prescription. By identifying drugs most likely to benefit a patient, assessing the likely dose response, potentially avoiding adverse reactions, and reducing unnecessary use of drugs, pharmacogenomics testing (PgX) has helped optimize treatment and reduce costs associated with complications or inappropriate utilization.
As research demonstrating the clinical utility and associated health economics benefits of PgX has grown—along with the soaring trend toward value-based healthcare—PgX services are now on the path to becoming the standard of care. This demand for PgX presents a tremendous opportunity for clinical laboratories, many of which have already over the last few years successfully launched PgX services, and enjoyed robust growth. (more…)
Sep 2, 2011 | Laboratory Management and Operations, Laboratory News, Laboratory Pathology
Web-based medical laboratory testing companies give consumers the option to purchase lab tests at cheap prices
It’s nearly impossible to do a web search for any term that includes “medical laboratory tests” and not have the search engine return paid listings for numerous clinical laboratory testing companies organized specifically to allow consumers to order their own lab tests over the Internet. This is a sign that the direct-to-consumer medical laboratory testing marketplace is booming.
These companies seem to be multiplying like rabbits. It is common to see such names as AccessaLabs.com, AnyLabTestNow.com, HealthOneLabs.com, PrePaidLabTests.com, and PrivateMDLabs.com pop up in the search engine. For a consumer looking to order their own clinical laboratory tests, these are enticing names. (more…)
May 25, 2010 | Coding, Billing, and Collections, Laboratory Pathology, Managed Care Contracts & Payer Reimbursement
Health insurers not eager to establish coverage for new molecular diagnostic assays
Navigating the pathway to successful commercialization of new genetic tests and molecular diagnostic assays has proven tricky. While scientists work quickly to bring new and better clinical laboratory testing tools to the market, health insurers work at a much slower pace to issue coverage guidelines and establish reimbursement for these new diagnostics tests.
“Successfully moving a genetic test from the research bench to the clinical laboratory takes much more than an understanding of the science,” stated Rina Wolf, Vice President of Commercialization Strategies for Consulting and Industry Affairs, XIFIN Inc., of San Diego, California. “Competition for coverage and reimbursement by health insurers is fierce. Often, the molecular diagnostic tests that win the best coverage decisions by payers are those proprietary tests backed by companies and laboratories with the most effective business plans.”
(more…)
